logo

For the Inventor, By the Inventor

Wachenheim, Germany

Albrecht Franke

USPTO Granted Patents = 29

Average Co-Inventor Count = 5.2

ph-index = 5

Forward Citations = 77(Granted Patents)


Location History:

  • Ludwigshafen, DE (1976 - 1977)
  • Wachenheim, DE (1979 - 1992)

Company Filing History:

goldMedal28 out of 10,754 
 
Basf Aktiengesellschaft
 patents
silverMedal1 out of 6,858 
 
Ciba-geigy Corporation
 patents

Years Active: 1976-1992

Loading Chart...
29 patents (USPTO):Explore Patents
1. 5118685 - Aminopropanol derivatives of substituted 2-hydroxy-propiophenones, and (1992-06-02),
2. 4873246 - 6-(acylaminoaryl)-3(2H)-pyridazinone derivatives, and their use (1989-10-10),
3. 4820821 - Novel pyridazinone-imines and their physiologically tolerated addition (1989-04-11),
4. 4636504 - 6-(acylaminoaryl)-3(2H)-pyridazinone derivatives and their use (1987-01-13),
5. 4612320 - Aminopropanol derivatives of 1-(2-hydroxyphenyl)-3-phenylpropanols and (1986-09-16),
6. 4571409 - Aminopropanol derivatives of 2-hydroxy-.beta.-phenyl-propiophenones, (1986-02-18),
7. 4563474 - Phthalimides and thienopyrrols as drugs (1986-01-07),
8. 4544562 - 6-Aryl-4,5-dihydro-3(2H)-pyridazinones, and their use as (1985-10-01),
9. 4540697 - Aminopropanol derivatives of 2-hydroxy-.beta.-phenyl-propiophenones, (1985-09-10),
10. 4514413 - Gastric acid secretion inhibiting N-(imidazol-1-ylalkyl)thiourea (1985-04-30),
11. 4474785 - 2-Aryl-3,4-diazabicyclo[4.n.O]alk-2-en-5-ones, and compositions for (1984-10-02),
12. 4428950 - (Hetarylphenoxy)-(phenylpiperazinyl)-propanols, their preparation and (1984-01-31),
13. 4415571 - Carbamate dihydropyridazinones, their preparation and therapeutic agents (1983-11-15),
14. 4388237 - 6(1-Piperazinyl), piperidino and (1(homopiperazinyl)11-cyanomethylene (1983-06-14),
15. 4353917 - Amino derivatives of 2-methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazole, (1982-10-12),

Certainly! Here is the article about inventor Albrecht Franke's remarkable journey:

Title: Albrecht Franke: A Trailblazer in Pharmaceutical Innovation

Introduction:

Albrecht Franke, hailing from Wachenheim, DE, is a visionary inventor whose unwavering commitment to innovation has left an indelible mark on the pharmaceutical industry. With an impressive portfolio of 29 patents, Franke's dedication to pushing boundaries and achieving excellence has not only transformed industries but also inspired a new generation of inventors.

Latest Patents:

Some of Franke's latest patents include groundbreaking inventions such as Aminopropanol derivatives and 6-(acylaminoaryl)-3(2H)-pyridazinone derivatives. These compounds have shown significant antiarrhythmic and thrombocyte aggregation-inhibiting activity, showcasing Franke's expertise in pharmaceutical innovation.

Career Highlights:

Having worked with renowned companies such as BASF Aktiengesellschaft and Ciba-Geigy Corporation, Franke has honed his skills and expertise in the field of pharmaceuticals. His innovative approach to drug development has led to the creation of novel compounds that have the potential to revolutionize the treatment of various medical conditions.

Collaborations:

Throughout his illustrious career, Franke has collaborated with esteemed colleagues such as Josef Gries and Dieter Lenke. Together, they have synergized their skills and knowledge to drive forward groundbreaking research in the pharmaceutical sector, leading to the development of cutting-edge compounds with life-changing potential.

Conclusion:

In conclusion, Albrecht Franke's journey as an inventor is a testament to his brilliance, tenacity, and passion for innovation. His contributions to the field of pharmaceuticals have not only advanced scientific knowledge but have also paved the way for transformative therapies. Franke's legacy serves as an inspiration for aspiring inventors and underscores the profound impact that innovation can have on society.

If you need any more information or details, feel free to ask!

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…